Next Article in Journal
Intraoperative Oliguria with Decreased SvO2 Predicts Acute Kidney Injury after Living Donor Liver Transplantation
Next Article in Special Issue
Usefulness of Eye Fixation Assessment for Identifying Type 2 Diabetic Subjects at Risk of Dementia
Previous Article in Journal
Comprehensive Lung Function Assessment Does not Allow to Infer Response to Pulmonary Rehabilitation in Patients with COPD
Previous Article in Special Issue
Association between End-Stage Renal Disease and Incident Diabetes Mellitus—A Nationwide Population-Based Cohort Study
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
J. Clin. Med. 2019, 8(1), 28; https://doi.org/10.3390/jcm8010028

Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study

1
Department of Medical Sciences, Ajou University Graduate School, Suwon 16499, Korea
2
Ministry of Health and Welfare, Gyeonggi Provincial Government, Suwon 16444, Korea
3
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Korea
4
Department of Neurology, Ajou University School of Medicine, Suwon 16499, Korea
*
Author to whom correspondence should be addressed.
Received: 12 November 2018 / Revised: 21 December 2018 / Accepted: 22 December 2018 / Published: 28 December 2018
(This article belongs to the Special Issue Clinical Research on Diabetic Complications)
Full-Text   |   PDF [1132 KB, uploaded 28 December 2018]   |  

Abstract

Background: Type 2 diabetes is related to an increased risk of dementia. Preclinical studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results. Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes on DPP-4is and sulfonylureas (SU). Methods: Using a claims database called the Korean National Health Insurance Service Senior cohort, new users of DPP-4is and SUs were matched by 1:1 propensity score matching using 49 confounding variables (7552 new DPP-4is users and 7552 new SU users were matched by 1:1 propensity score matching; average age 75.4; mean follow-up period: 1361.9 days). Survival analysis was performed to estimate the risk of dementia. Results: The risk of all-cause dementia was lower in the DPP-4i group compared to the SU group (hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.56–0.78; p < 0.001). Particularly, DPP-4i use showed a significantly lower risk of Alzheimer’s disease (HR 0.64; 95% CI 0.52–0.79; p < 0.001) and a lower risk, albeit non-significant, of vascular dementia compared to SU use (HR 0.66; 95% CI 0.38–1.14; p = 0.139). Conclusion: Our findings suggest that DPP-4i use decreases the risk of dementia compared to SU use in elderly patients with type 2 diabetes in a real-world clinical setting. View Full-Text
Keywords: dementia; dipeptidyl-peptidase IV inhibitors; diabetes mellitus; type 2; Alzheimer’s disease; dementia; vascular dementia; dipeptidyl-peptidase IV inhibitors; diabetes mellitus; type 2; Alzheimer’s disease; dementia; vascular
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kim, Y.-G.; Jeon, J.Y.; Kim, H.J.; Kim, D.J.; Lee, K.-W.; Moon, S.Y.; Han, S.J. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. J. Clin. Med. 2019, 8, 28.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top